Vistagen Therapeutics (VTGN) Share-based Compensation (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Share-based Compensation of $889000.0 for Q1 2026, down 18.89% sequentially from $1.1 million in Q4 2025, and down 7.68% YoY from $963000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Share-based Compensation (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $889000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 7.68% year-over-year to $889000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 7.37% YoY) and the FY2026 annual result came in at $4.0 million, down 7.37% from the prior year.
- Share-based Compensation slipped to $889000.0 in Q1 2026 per VTGN's latest filing, from $1.1 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.4 million in Q1 2022 and troughed at $506700.0 in Q4 2023.
- A 5-year average of $895970.6 and a median of $956900.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 186.01% in 2022, then plunged 57.13% in 2023.
- Over 5 years, Share-based Compensation stood at $746300.0 in 2022, then sank by 32.11% to $506700.0 in 2023, then jumped by 113.14% to $1.1 million in 2024, then advanced by 1.48% to $1.1 million in 2025, then dropped by 18.89% to $889000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $889000.0, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.39 Mn | 10.39 Mn | - | 991,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 889,000.00 |
| Mar 31, 2026 | 889,000.00 |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 916,000.00 |
| Jun 30, 2025 | 916,000.00 |
| Mar 31, 2025 | 963,000.00 |
| Mar 31, 2025 | 963,000.00 |
| Dec 31, 2024 | 1.08 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 522,000.00 |
| Mar 31, 2024 | 522,000.00 |
| Dec 31, 2023 | 506,700.00 |
| Dec 31, 2023 | 506,700.00 |